X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	127	140	69	57	105	133
Market Cap Growth	119.56%	104.03%	21.51%	-45.97%	-21.43%	301.31%
Enterprise Value	105	84	-15	15	64	30
PE Ratio	-	-1.39	-0.71	-0.55	-1.69	-2.50
PS Ratio	-	-	-	-	34.91	-
PB Ratio	123.04	2.75	0.93	0.88	1.44	1.03
P/FCF Ratio	-2.25	-1.45	-0.89	-0.79	-1.74	-2.76
P/OCF Ratio	-2.25	-1.45	-0.89	-0.80	-1.78	-2.77
EV/Sales Ratio	-	-	-	-	21.49	-
EV/EBITDA Ratio	-1.75	-0.90	0.17	-0.18	-1.11	-0.60
EV/EBIT Ratio	-1.72	-0.88	0.16	-0.17	-1.09	-0.59
EV/FCF Ratio	-2.03	-0.87	0.19	-0.20	-1.07	-0.62
Debt / Equity Ratio	56.25	1.14	0.52	0.62	0.53	0.18
Debt / EBITDA Ratio	-0.48	-0.62	-0.44	-0.48	-0.66	-0.46
Debt / FCF Ratio	-0.56	-0.60	-0.50	-0.56	-0.64	-0.48
Quick Ratio	3.47	5.02	5.50	5.89	6.66	13.57
Current Ratio	3.71	5.34	5.76	6.27	6.97	13.69
Asset Turnover	0	0	0	0	0.02	0
Interest Coverage	-18.69	-16.50	-22.50	-23.35	-22.06	-23.60
Return on Equity (ROE)	-275.40%	-170.10%	-178.80%	-126.10%	-64.40%	-64.00%
Return on Assets (ROA)	-85.10%	-65.40%	-85.80%	-76.00%	-45.00%	-45.80%
Return on Capital (ROIC)	-195.09%	-98.30%	-77.86%	-81.68%	-53.82%	-33.99%
Earnings Yield	-101.14%	-72.12%	-140.24%	-181.40%	-59.33%	-40.06%
FCF Yield	-81.36%	-68.85%	-112.30%	-126.40%	-57.47%	-36.19%
Buyback Yield / Dilution	-37.01%	-179.91%	-146.71%	-28.25%	-74.13%	-2411.98%
Total Shareholder Return	-37.01%	-179.91%	-146.71%	-28.25%	-74.13%	-2411.98%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).